Relative dose intensity: improving cancer treatment and outcomes.
OBJECTIVE
To determine the incidence of and reasons for chemotherapy dose delays or reductions.


METHODS
A performance improvement initiative formed the basis for a prospective nursing research study.


METHODS
A single institution in western Pennsylvania.


METHODS
204 patients scheduled for nonmyeloablative chemo-therapy.


METHODS
Data collection forms were completed by RNs and evaluated by an interdisciplinary team.


METHODS
Rates of nonadherence to chemotherapy schedule or dosing and associated reasons.


RESULTS
The performance improvement initiative revealed evidence of nonadherence to chemotherapy schedule or dosing when patient-requested cancellations and physician-ordered dose delays and reductions were left unchallenged and medical and nursing staffs had limited knowledge of or interest in relative dose intensity. The ensuing nursing research study found that less than 51% and 78% of patients adhered to their schedule and dosage, respectively. Nonadherence primarily was attributed to canceled visits, suboptimal or nonuse of hematopoietic growth factors, and routine dose reductions. Subsequent educational initiatives targeting the interdisciplinary team and patients and their families focused on the importance of keeping scheduled visits and preventing versus managing pancytopenia. Adopting a telephone referral procedure and distributing a patient education sheet reduced patient cancellations by 50%. Various reasons for dose delays and reductions have surfaced, many of which are modifiable with educational efforts.


CONCLUSIONS
A knowledge deficit was found among patients and healthcare providers regarding the importance of adhering to chemo-therapy orders.


CONCLUSIONS
Evaluating patterns of chemotherapy administration and educating patients, nurses, and physicians will have an impact on relative dose intensity, potentially improving treatment outcomes.
Lenhart
Cheryl
C
Medical Short Stay Center, Western Pennsylvania Hospital, Pittsburgh, USA. clenhart@wpahs.org
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000451:nursing; D010349:Patient Compliance; D011446:Prospective Studies; D016896:Treatment Outcome
D000970:Antineoplastic Agents